DK3653644T3 - Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft - Google Patents

Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft Download PDF

Info

Publication number
DK3653644T3
DK3653644T3 DK19205321.3T DK19205321T DK3653644T3 DK 3653644 T3 DK3653644 T3 DK 3653644T3 DK 19205321 T DK19205321 T DK 19205321T DK 3653644 T3 DK3653644 T3 DK 3653644T3
Authority
DK
Denmark
Prior art keywords
cancer
cachesia
gdf
treatment
monoclonal antibodies
Prior art date
Application number
DK19205321.3T
Other languages
English (en)
Inventor
Jörg Wischhusen
Markus Junker
Tina Schäfer
Dirk Pühringer
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Application granted granted Critical
Publication of DK3653644T3 publication Critical patent/DK3653644T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK19205321.3T 2014-03-26 2015-03-26 Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft DK3653644T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
EP15712629.3A EP3122775B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Publications (1)

Publication Number Publication Date
DK3653644T3 true DK3653644T3 (da) 2023-12-18

Family

ID=52745885

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15712629.3T DK3122775T3 (da) 2014-03-26 2015-03-26 Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
DK19205321.3T DK3653644T3 (da) 2014-03-26 2015-03-26 Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15712629.3T DK3122775T3 (da) 2014-03-26 2015-03-26 Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer

Country Status (22)

Country Link
US (5) US20170204174A1 (da)
EP (3) EP3653644B1 (da)
JP (3) JP6865585B2 (da)
KR (1) KR102520978B1 (da)
CN (1) CN106536553B (da)
AU (2) AU2015238264B2 (da)
BR (1) BR122023027559A2 (da)
CA (1) CA2943694A1 (da)
CY (1) CY1122456T1 (da)
DK (2) DK3122775T3 (da)
ES (2) ES2965626T3 (da)
FI (1) FI3653644T3 (da)
HR (2) HRP20231514T1 (da)
HU (2) HUE047398T2 (da)
IL (2) IL248038B (da)
LT (2) LT3122775T (da)
NZ (1) NZ724649A (da)
PL (2) PL3122775T3 (da)
PT (2) PT3653644T (da)
RS (1) RS59700B1 (da)
SI (1) SI3122775T1 (da)
WO (1) WO2015144855A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047398T2 (hu) 2014-03-26 2020-04-28 Univ Wuerzburg J Maximilians Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére
WO2016049470A1 (en) 2014-09-25 2016-03-31 Aveo Pharmaceuticals, Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
AU2016333538B2 (en) * 2015-10-02 2022-03-31 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
WO2017055613A2 (en) * 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
CA3029136A1 (en) * 2016-07-06 2018-01-11 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
WO2018071493A1 (en) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
AU2017371382A1 (en) * 2016-12-06 2019-06-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
TWI803682B (zh) * 2018-08-20 2023-06-01 美商輝瑞股份有限公司 抗-gdf15抗體、組成物及使用方法
WO2022101263A1 (en) * 2020-11-10 2022-05-19 Catalym Gmbh Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
MX2023011655A (es) 2021-03-31 2023-10-11 Cambridge Entpr Ltd Inhibidores terapeuticos de la se?alizacion de gdf15.
AU2022328390A1 (en) 2021-08-10 2024-03-21 Adimab, Llc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023217068A1 (zh) * 2022-05-09 2023-11-16 舒泰神(北京)生物制药股份有限公司 特异性识别gdf15的抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
JP2002543841A (ja) 1999-05-17 2002-12-24 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー TGF−βスーパーファミリーの新規のメンバーであるGDF―15の神経保護特性
AU2001288770A1 (en) 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
HUE026132T2 (en) * 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
JP2011502106A (ja) * 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−1を除去又は不活性化して悪液質を治療する方法
CN102164959A (zh) 2008-09-29 2011-08-24 罗氏格黎卡特股份公司 针对人il17的抗体及其应用
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
PT2644698T (pt) * 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
TR201910744T4 (tr) * 2012-09-26 2019-08-21 Univ Wuerzburg J Maximilians Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar.
DK2934584T3 (da) 2012-12-21 2020-05-18 Aveo Pharmaceuticals Inc Anti-gdf15-antistoffer
HUE047398T2 (hu) 2014-03-26 2020-04-28 Univ Wuerzburg J Maximilians Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére

Also Published As

Publication number Publication date
EP4316596A3 (en) 2024-04-17
HUE064573T2 (hu) 2024-03-28
BR112016022013A2 (pt) 2017-10-31
EP4316596A2 (en) 2024-02-07
US10604565B2 (en) 2020-03-31
JP2021119138A (ja) 2021-08-12
AU2015238264A1 (en) 2016-10-20
US20180298091A1 (en) 2018-10-18
KR20160139005A (ko) 2016-12-06
US11634482B2 (en) 2023-04-25
US20200308265A1 (en) 2020-10-01
PT3653644T (pt) 2023-12-19
CN106536553B (zh) 2021-03-12
JP2023098966A (ja) 2023-07-11
EP3653644B1 (en) 2023-11-15
PL3122775T3 (pl) 2020-05-18
IL248038B (en) 2020-08-31
BR122023027559A2 (pt) 2024-01-30
DK3122775T3 (da) 2020-02-03
EP3653644A1 (en) 2020-05-20
PT3122775T (pt) 2019-12-26
IL248038A0 (en) 2016-11-30
ES2965626T3 (es) 2024-04-16
LT3122775T (lt) 2020-02-10
US20200308264A1 (en) 2020-10-01
FI3653644T3 (fi) 2023-12-12
PL3653644T3 (pl) 2024-03-04
HUE047398T2 (hu) 2020-04-28
LT3653644T (lt) 2024-01-25
IL276405B (en) 2021-07-29
AU2020260440A1 (en) 2020-11-26
CY1122456T1 (el) 2021-01-27
ES2763859T3 (es) 2020-06-01
RS59700B1 (sr) 2020-01-31
KR102520978B1 (ko) 2023-04-11
SI3122775T1 (sl) 2020-02-28
AU2020260440B2 (en) 2024-03-21
IL276405A (en) 2020-09-30
JP6865585B2 (ja) 2021-04-28
US11760795B2 (en) 2023-09-19
AU2015238264B2 (en) 2020-09-03
CN106536553A (zh) 2017-03-22
US20230382987A1 (en) 2023-11-30
JP2017508475A (ja) 2017-03-30
CA2943694A1 (en) 2015-10-01
NZ724649A (en) 2022-07-01
US20170204174A1 (en) 2017-07-20
HRP20231514T1 (hr) 2024-03-01
HRP20200034T1 (hr) 2020-03-20
EP3122775A1 (en) 2017-02-01
WO2015144855A1 (en) 2015-10-01
EP3122775B1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
DK3653644T3 (da) Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
HK1245134A1 (zh) 用抗lap單克隆抗體治療癌症
DK3565844T3 (da) Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
DK3307322T3 (da) Humaniserede anti-cd40-antistoffer og anvendelser deraf
DK3508502T3 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3455259T3 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK3303394T3 (da) Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3142751T3 (da) Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer
DK3274370T3 (da) Anti-ceacam6-antistoffer og anvendelser deraf
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
DK3474841T3 (da) Fremgangsmåder til behandling af ar+-brystkræft
DK3280440T3 (da) Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
DK3114142T3 (da) Insulinlignende vækstfaktor 1-receptorspecifikke antistoffer og anvendelser deraf
DK3445785T3 (da) Humaniserede anti-clever-1-antistoffer og anvendelse deraf
IL258515A (en) Treatment methods using anti-il-17a/f antibodies
DK3209686T3 (da) Monoklonale anti-gpc-1-antistoffer og anvendelser deraf
DK3349731T3 (da) Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft
DK3313528T3 (da) Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer
GB2524553C (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer